Accrued Milestone Payments

No definition available.

Name:	biib_AccruedMilestonePayments
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaboration profit (loss) sharing

+ References

No definition available.

+ Details

Name:	biib_Collaborationprofitlosssharing
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement, Contract Option Exercise Fee Paid

+ References

No definition available.

+ Details

Name:	biib_CollaborativeArrangementContractOptionExerciseFeePaid
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement, Term Extension

+ References

No definition available.

+ Details

Name:	biib_CollaborativeArrangementTermExtension
Namespace Prefix:	biib_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Contingent Commercialized Rights, Number Of Products

+ References

No definition available.

+ Details

Name:	biib_ContingentCommercializedRightsNumberOfProducts
Namespace Prefix:	biib_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Contract Option Exercise Fee

+ References

No definition available.

+ Details

Name:	biib_ContractOptionExerciseFee
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Equity Method Investments, Expected Profit Share

+ References

No definition available.

+ Details

Name:	biib_EquityMethodInvestmentsExpectedProfitShare
Namespace Prefix:	biib_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Estimated additional payments upon achievement of development and commercial milestones.

+ References

No definition available.

+ Details

Name:	biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(15)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

+ Details

Name:	us-gaap_AccountsPayableCurrentAndNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 310
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477802/946-310-45-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(5)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 954
-SubTopic 310
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479196/954-310-45-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

+ Details

Name:	us-gaap_AccountsReceivableNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative and Other Relationships - Samsung Bioepis (Details) $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended
	Dec. 31, 2019 product	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Collaborative arrangements and non-collaborative arrangement transactions
Collaboration profit sharing/(loss reimbursement)		$ 62.4	$ 56.9	$ 128.0	$ 114.0
Samsung Bioepis
Collaborative arrangements and non-collaborative arrangement transactions
Collaboration profit sharing/(loss reimbursement)		55.9	$ 56.9	$ 116.5	$ 114.0
Samsung Bioepis
Collaborative arrangements and non-collaborative arrangement transactions
Contingent Commercialized Rights, Number Of Products \| product	2
Expected profit share percentage	45.00%			50.00%
Accrued milestone payments		15.0
Estimated additional payments upon achievement of development and commercial milestones				$ 165.0
Collaboration agreement term				5 years
Option exercise fee				$ 60.0
Option exercise fee paid				60.0
Samsung Bioepis \| Related Party
Collaborative arrangements and non-collaborative arrangement transactions
Accounts receivable		19.0		19.0		$ 9.9
Accounts payable		$ 93.6		$ 93.6		$ 73.7